Total Payments
$72,344
2024 Payments
$27,537
Companies
14
Transactions
119
Payment Breakdown by Category
Consulting$39,497 (54.6%)
Travel$18,085 (25.0%)
Research$7,971 (11.0%)
Food & Beverage$4,001 (5.5%)
Other$2,790 (3.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,497 | 13 | 54.6% |
| Travel and Lodging | $18,085 | 30 | 25.0% |
| Unspecified | $7,971 | 18 | 11.0% |
| Food and Beverage | $4,001 | 57 | 5.5% |
| Honoraria | $2,790 | 1 | 3.9% |
Payments by Type
General
$64,373
101 transactions
Research
$7,971
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $26,902 | 28 | $0 (2024) |
| Incyte Corporation | $20,687 | 41 | $0 (2024) |
| CSL Behring | $10,246 | 9 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $5,571 | 11 | $0 (2021) |
| Horizon Therapeutics plc | $2,790 | 1 | $0 (2021) |
| Mallinckrodt LLC | $1,747 | 4 | $0 (2017) |
| National Marrow Donor Program | $1,600 | 6 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $1,045 | 9 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,010 | 1 | $0 (2021) |
| Genentech USA, Inc. | $260.86 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,537 | 35 | SANOFI-AVENTIS U.S. LLC ($19,850) |
| 2023 | $13,878 | 25 | Incyte Corporation ($6,796) |
| 2022 | $8,214 | 21 | Incyte Corporation ($7,020) |
| 2021 | $4,081 | 5 | Horizon Therapeutics plc ($2,790) |
| 2019 | $15,851 | 21 | CSL Behring ($10,246) |
| 2018 | $323.78 | 4 | Novartis Pharmaceuticals Corporation ($323.78) |
| 2017 | $2,459 | 8 | Mallinckrodt LLC ($1,747) |
All Payment Transactions
119 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Consulting Fee | Cash or cash equivalent | $9,970.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | In-kind items and services | $3,239.64 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | In-kind items and services | $426.03 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $136.38 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | In-kind items and services | $121.15 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | Cash or cash equivalent | $103.70 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $73.22 | General |
| Category: Oncology | ||||||
| 11/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Travel and Lodging | Cash or cash equivalent | $49.98 | General |
| Category: Oncology | ||||||
| 10/25/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $29.71 | General |
| Category: Oncology | ||||||
| 09/30/2024 | National Marrow Donor Program | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 09/05/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $31.10 | General |
| Category: Rare Disease | ||||||
| 08/08/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $5,625.00 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $326.84 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $256.95 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.48 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $53.24 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $29.87 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $6.94 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $219.00 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $52.01 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $6.94 | General |
| 07/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $50.58 | General |
| Category: Hematology/Oncology | ||||||
| 07/05/2024 | SANOFI-AVENTIS U.S. LLC | REZUROCK (Drug) | Food and Beverage | In-kind items and services | $42.78 | General |
| Category: Oncology | ||||||
| 04/12/2024 | National Marrow Donor Program | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $4,495 | 2 |
| SINGLE-ARM STUDY TO ASSESS THE EFFICACY OF UVADEX (METHOXSALEN) STERILE SOLUTION IN CONJUNCTION WITH THE THERAKOS CELLEX PHOTOPHERESIS SYSTEM IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) | Mallinckrodt LLC | $1,710 | 3 |
| PCYC-1146-IM | Pharmacyclics LLC, An AbbVie Company | $1,045 | 9 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $721.72 | 4 |
About Dr. Andrew Harris, M.D
Dr. Andrew Harris, M.D is a Pediatrics healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356546493.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Harris, M.D has received a total of $72,344 in payments from pharmaceutical and medical device companies, with $27,537 received in 2024. These payments were reported across 119 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($39,497).
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Pediatric Hematology-Oncology, Pediatric Hematology-Oncology
- Location New York, NY
- Active Since 06/19/2007
- Last Updated 08/13/2021
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1356546493
Products in Payments
- REZUROCK (Drug) $14,854
- KYMRIAH (Biological) $4,749
- ACTIMMUNE (Drug) $2,790
- UVADEX (METHOXSALEN) STERILE SOLUTION (Drug) $1,747
- Ibrutinib (Drug) $1,045
- IMBRUVICA (Drug) $1,010
- JAKAFI (Drug) $529.66
- GAMIFANT (Drug) $234.65
- ADCETRIS (Biological) $86.09
- Kcentra (Biological) $77.32
- ULTOMIRIS (Biological) $46.66
- DANYELZA (Drug) $22.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in New York
James Bussel, Md, MD
Pediatrics — Payments: $347,063
Pediatrics $347,063
Rosandra Reich Kaplan, M.d, M.D
Pediatrics — Payments: $300,614
Pediatrics $300,614
Dr. Michael Dolinger, Md, Mba, MD, MBA
Pediatrics — Payments: $143,865
Pediatrics $143,865
Shakeel Modak, Mbbs, MBBS
Pediatrics — Payments: $109,015
Pediatrics $109,015
Dr. George Diaz, M.d., Ph.d, M.D., PH.D
Pediatrics — Payments: $87,870
Pediatrics $87,870
Kaleb Yohay, M.d, M.D
Pediatrics — Payments: $85,737
Pediatrics $85,737